A nem alkoholos zsírmáj és a szív-ér rendszeri kockázat

Translated title of the contribution: Non-alcoholic fatty liver disease and cardiovascular risk

Tatjána Ábel, J. Fehér

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease is present in 15-25% of the general population. The fundamental derangement in non-alcoholic fatty liver disease is insulin resistance, a key component of the metabolic syndrome, which includes type 2 diabetes mellitus, dyslipidemia, hypertension, and obesity. The natural history of non-alcoholic fatty liver disease is not always benign, and causality for chronic liver disease and cirrhosis is well known in clinical practice and sometimes it is accompanied by hepatocellular carcinoma. Non-alcoholic fatty liver disease is likely to be associated with increased cardiovascular disease risk, and it raises the possibility that non-alcoholic fatty liver disease may be not only a marker but also an early mediator of atherosclerosis. Therapy is currently directed at treating components of the metabolic syndrome which may be beneficial also for the liver.

Original languageHungarian
Pages (from-to)1299-1305
Number of pages7
JournalOrvosi Hetilap
Volume149
Issue number28
DOIs
Publication statusPublished - Jul 13 2008

Fingerprint

Dyslipidemias
Liver Cirrhosis
Causality
Type 2 Diabetes Mellitus
Insulin Resistance
Liver Diseases
Hepatocellular Carcinoma
Atherosclerosis
Chronic Disease
Cardiovascular Diseases
Obesity
Non-alcoholic Fatty Liver Disease
Hypertension
Liver
Population
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A nem alkoholos zsírmáj és a szív-ér rendszeri kockázat. / Ábel, Tatjána; Fehér, J.

In: Orvosi Hetilap, Vol. 149, No. 28, 13.07.2008, p. 1299-1305.

Research output: Contribution to journalArticle

Ábel, Tatjána ; Fehér, J. / A nem alkoholos zsírmáj és a szív-ér rendszeri kockázat. In: Orvosi Hetilap. 2008 ; Vol. 149, No. 28. pp. 1299-1305.
@article{51fd3a885d1f4979827ebd14cbfeae88,
title = "A nem alkoholos zs{\'i}rm{\'a}j {\'e}s a sz{\'i}v-{\'e}r rendszeri kock{\'a}zat",
abstract = "Non-alcoholic fatty liver disease is present in 15-25{\%} of the general population. The fundamental derangement in non-alcoholic fatty liver disease is insulin resistance, a key component of the metabolic syndrome, which includes type 2 diabetes mellitus, dyslipidemia, hypertension, and obesity. The natural history of non-alcoholic fatty liver disease is not always benign, and causality for chronic liver disease and cirrhosis is well known in clinical practice and sometimes it is accompanied by hepatocellular carcinoma. Non-alcoholic fatty liver disease is likely to be associated with increased cardiovascular disease risk, and it raises the possibility that non-alcoholic fatty liver disease may be not only a marker but also an early mediator of atherosclerosis. Therapy is currently directed at treating components of the metabolic syndrome which may be beneficial also for the liver.",
keywords = "Cardiovascular risk, Non-alcoholic fatty liver, Treatment",
author = "Tatj{\'a}na {\'A}bel and J. Feh{\'e}r",
year = "2008",
month = "7",
day = "13",
doi = "10.1556/OH.2008.28418",
language = "Hungarian",
volume = "149",
pages = "1299--1305",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "28",

}

TY - JOUR

T1 - A nem alkoholos zsírmáj és a szív-ér rendszeri kockázat

AU - Ábel, Tatjána

AU - Fehér, J.

PY - 2008/7/13

Y1 - 2008/7/13

N2 - Non-alcoholic fatty liver disease is present in 15-25% of the general population. The fundamental derangement in non-alcoholic fatty liver disease is insulin resistance, a key component of the metabolic syndrome, which includes type 2 diabetes mellitus, dyslipidemia, hypertension, and obesity. The natural history of non-alcoholic fatty liver disease is not always benign, and causality for chronic liver disease and cirrhosis is well known in clinical practice and sometimes it is accompanied by hepatocellular carcinoma. Non-alcoholic fatty liver disease is likely to be associated with increased cardiovascular disease risk, and it raises the possibility that non-alcoholic fatty liver disease may be not only a marker but also an early mediator of atherosclerosis. Therapy is currently directed at treating components of the metabolic syndrome which may be beneficial also for the liver.

AB - Non-alcoholic fatty liver disease is present in 15-25% of the general population. The fundamental derangement in non-alcoholic fatty liver disease is insulin resistance, a key component of the metabolic syndrome, which includes type 2 diabetes mellitus, dyslipidemia, hypertension, and obesity. The natural history of non-alcoholic fatty liver disease is not always benign, and causality for chronic liver disease and cirrhosis is well known in clinical practice and sometimes it is accompanied by hepatocellular carcinoma. Non-alcoholic fatty liver disease is likely to be associated with increased cardiovascular disease risk, and it raises the possibility that non-alcoholic fatty liver disease may be not only a marker but also an early mediator of atherosclerosis. Therapy is currently directed at treating components of the metabolic syndrome which may be beneficial also for the liver.

KW - Cardiovascular risk

KW - Non-alcoholic fatty liver

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=48749102253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48749102253&partnerID=8YFLogxK

U2 - 10.1556/OH.2008.28418

DO - 10.1556/OH.2008.28418

M3 - Article

VL - 149

SP - 1299

EP - 1305

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 28

ER -